Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 365 DKK -2.67% Market Closed
Market Cap: 25.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

Relative Value

The Relative Value of one ZEAL stock under the Base Case scenario is 141.69 DKK. Compared to the current market price of 365 DKK, Zealand Pharma A/S is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZEAL Relative Value
Base Case
141.69 DKK
Overvaluation 61%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
15
vs Industry
5
Median 3Y
116.5
Median 5Y
74.1
Industry
7.3
Forward
6.7
vs History
vs Industry
Median 3Y
-22.8
Median 5Y
-13.8
Industry
23.3
Forward
54.1
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-14.5
Industry
19.8
vs History
vs Industry
Median 3Y
-20.4
Median 5Y
-11.4
Industry
22.6
vs History
98
vs Industry
20
Median 3Y
9.6
Median 5Y
6.7
Industry
2.7
vs History
15
vs Industry
5
Median 3Y
112.2
Median 5Y
73.2
Industry
7.6
Forward
4.6
vs History
15
vs Industry
3
Median 3Y
95
Median 5Y
58.8
Industry
9.4
vs History
vs Industry
Median 3Y
-18
Median 5Y
-13.6
Industry
4.7
Forward
31.1
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-12.7
Industry
4.8
Forward
3
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-12.7
Industry
5.3
vs History
vs Industry
Median 3Y
-20.2
Median 5Y
-12.2
Industry
3.8
vs History
36
vs Industry
8
Median 3Y
54.5
Median 5Y
38.1
Industry
5

Multiples Across Competitors

ZEAL Competitors Multiples
Zealand Pharma A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
25.8B DKK 462.9 -21.7 -12.8 -12.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 841 650.5 -160 844.3 -195 316.3 -193 087.6
US
Abbvie Inc
NYSE:ABBV
336.7B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.4B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
141B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.1B USD 11.1 -124.5 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.7 -531.2 -578.4 -563
AU
CSL Ltd
ASX:CSL
117B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.8B USD 4.2 13.3 11.9 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD 17.8 -155 -695.4 -348.5
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/S: 3 076 751.7
462.9
205%
2.3
FR
Pharnext SCA
OTC:PNEXF
33 841 650.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.1
10%
1.1
US
E
Epizyme Inc
F:EPE
2 081.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.8
29%
0.6
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 34.5
Negative Multiple: -21.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 844.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 15.9
Negative Multiple: -12.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -695.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 20.6
Negative Multiple: -12.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 087.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -348.5 N/A N/A